Prescott General Partners LLC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Prescott General Partners LLC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$2,185,184
-16.3%
1,851,8510.0%0.14%
-13.7%
Q2 2023$2,611,110
-6.0%
1,851,8510.0%0.16%
-26.8%
Q1 2023$2,777,777
+28.2%
1,851,8510.0%0.22%
+25.0%
Q4 2022$2,166,666
+3.5%
1,851,8510.0%0.18%
+7.3%
Q3 2022$2,093,000
-28.5%
1,851,8510.0%0.16%
-18.4%
Q2 2022$2,926,000
+2.6%
1,851,8510.0%0.20%
+54.6%
Q1 2022$2,852,000
-37.1%
1,851,8510.0%0.13%
-16.1%
Q4 2021$4,537,000
-2.8%
1,851,8510.0%0.16%
-1.3%
Q3 2021$4,667,000
-11.6%
1,851,8510.0%0.16%
-8.7%
Q2 2021$5,278,000
+21.3%
1,851,8510.0%0.17%
+14.7%
Q1 2021$4,352,000
+33.5%
1,851,8510.0%0.15%
+10.3%
Q4 2020$3,259,000
+87.9%
1,851,8510.0%0.14%
+97.1%
Q3 2020$1,734,000
+7.6%
1,851,8510.0%0.07%0.0%
Q2 2020$1,611,000
+5.0%
1,851,8510.0%0.07%
-47.7%
Q1 2020$1,534,000
-6.9%
1,851,8510.0%0.13%
+78.4%
Q4 2019$1,648,000
-9.2%
1,851,8510.0%0.07%
+4.2%
Q3 2019$1,815,0001,851,8510.07%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2022
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$39,477,0003.01%
Raffles Associates 2,080,536$2,351,0002.51%
Defender Capital, LLC. 5,184,035$5,862,0002.30%
Prescott General Partners LLC 1,851,851$2,093,0000.16%
DAFNA Capital Management LLC 140,000$158,0000.04%
Fort Sheridan Advisors LLC 83,931$95,0000.03%
Long Focus Capital Management, LLC 215,000$243,0000.02%
XTX Topco Ltd 72,807$82,0000.02%
Ergoteles LLC 490,895$555,0000.02%
Beirne Wealth Consulting Services, LLC 45,000$51,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders